All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

New Drug Potentially Blocks HPV from Causing Head and Neck Cancer

April 17th 2013

A novel small molecule inhibitor called CH1iB may be able to block a mechanism that enables human papilloma virus to cause head and neck cancer.

Trials in Progress: Bone Metastases

April 16th 2013

The Trials in Progress series is intended to stimulate discussion about ongoing clinical trials, to promote collaboration across the oncology community.

Microwave Ablation Is Potentially Effective in Treating Bone and Soft-Tissue Tumor Pain

April 15th 2013

A small study found that microwave ablation therapy reduced pain associated with bone and soft tissues by half in the majority of patients treated with the technique.

Chime in on Oral Cancer Screening Recommendations

April 15th 2013

USPSTF is inviting comments on screening by primary care professionals.

Palbociclib Receives Breakthrough Designation for Treatment of Breast Cancer

April 10th 2013

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

AACR Rally Protests Cuts to NIH Budget

April 8th 2013

Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.

Ibrutinib Receives Additional Breakthrough Designation for CLL

April 8th 2013

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Melanoma

April 8th 2013

Melanoma is on the rise in children and teenagers.

Medicare Reimbursement Cuts Caused by Sequestration Begin to Take Effect

April 4th 2013

As a result of sequestration-related federal budget cuts, Medicare reimbursement has been reduced by 2% across the board, with the reduction affecting a number of services offered to cancer patients.

OncLive Collaborates With Renowned Cancer Centers

April 2nd 2013

Dana-Farber Cancer Institute and Seattle Cancer Care Alliance Join OncLive's Strategic Alliance Partnership Program.

Good News for Cancer Survivorship

March 25th 2013

The number of cancer survivors in the US continues to rise.

Novel Oncolytic Virus Effective in Melanoma

March 22nd 2013

The novel immunotherapy talimogene laherparepvec has become the first oncolytic virus to successfully complete a phase III trial in advanced melanoma.

Novel Compound LDK378 Receives Breakthrough Designation for ALK+ NSCLC

March 15th 2013

The compound LDK378, a highly selective inhibitor of ALK, has been granted "Breakthrough Therapy Designation" by the FDA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer.

Lymphoseek Approved to Help Detect Lymph Nodes in Breast Cancer and Melanoma

March 13th 2013

The FDA approved the radioactive diagnostic imaging agent technetium Tc 99m tilmanocept (Lymphoseek Injection) to identify lymph nodes for potential removal in patients with breast cancer or melanoma.

Nurses' Educational Preparation and Patient Outcomes

March 12th 2013

RNs with baccalaureate degrees provide the best post-surgical care.

Electronic Medical Record Adoption

March 6th 2013

A money-losing proposition for most practices.

Sequestration Takes Effect, Imposes Major Cuts to Cancer Research and Care

March 2nd 2013

Two months after temporarily delaying a package of budget cuts and tax increases, federal lawmakers allowed the changes to automatically take effect by failing to agree on an alternative plan.

Regorafenib Approved to Treat GIST

February 25th 2013

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

Lung Cancer Risk Prediction Model

February 25th 2013

Using different selection criteria for screening is superior to currently recommended criteria.

T-DM1 Approved for HER2-Positive Metastatic Breast Cancer

February 22nd 2013

The FDA has approved ado-trastuzumab emtansine, also known as T-DM1, for HER2-positive metastatic breast cancer.